This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Foxo1-nRNA
The nRNA technology platform is essentially antisense siRNA gene silencing. The company's proprietary chemistry allows the production of a chirally pure RNA that is proposed to result in more efficient targeting/silencing with less toxicity.The nRNAs are also proposed to be more stable and allow for more routes of administration.
Foxo1-nRNA targets Foxo-1, which is markedly upregulated in skeletal muscle in energy-deprived states such as fasting, cancer and severe diabetes. Foxo-1 is involved in the regulation of muscle development. In preclinical models, Foxo-1 stimulates fusion of myoblasts to myotube and regulates various cellular functions, including cell cycle and apoptosis.
Additional information available to subscribers only: